Longboard Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Longboard Pharmaceuticals han disminuido a una tasa media anual de -33.5%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.2% anualmente.

Información clave

-33.5%

Tasa de crecimiento de los beneficios

13.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-27.7%
Margen neto	n/a
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Desglose de ingresos y gastos

Cómo gana y gasta dinero Longboard Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:LBPH Ingresos, gastos y beneficios (USD Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	-76	20	67
30 Jun 24	-65	17	56
31 Mar 24	-58	15	48
31 Dec 23	-54	13	44
30 Sep 23	-51	12	41
30 Jun 23	-49	12	40
31 Mar 23	-46	11	36
31 Dec 22	-44	10	35
30 Sep 22	-41	10	32
30 Jun 22	-36	10	27
31 Mar 22	-32	9	22
31 Dec 21	-28	8	20
30 Sep 21	-29	6	16
30 Jun 21	-25	5	13
31 Mar 21	-20	4	9

Ingresos de calidad: LBPH actualmente no es rentable.

Margen de beneficios creciente: LBPH actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: LBPH no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 33.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de LBPH en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: LBPH no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (54.6%).

Rentabilidad financiera

Alta ROE: LBPH tiene una rentabilidad financiera negativa (-27.74%), ya que actualmente no es rentable.

Longboard Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Recent updates

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

High number of new and inexperienced directors

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Price target decreased to US$19.74

Price target decreased to US$22.80

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals Provides Corporate Update

Longboard Pharmaceuticals EPS beats by $0.29

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado